performance during first with On call, and Good I afternoon us. execution will Eric. start the our brief of thank a today's you joining for quarter. review Thanks, and
to the of I investment and business our achieve across our over turn on Justin vision vision. views Next, I Biology for a our will current then call more this Century to the the for will market we discuss continue detailed to got adoption quarter to first strong as at XX% $XXX Visium Chromium to revenues and year-over-year, growing outlook We for year. platforms. of a our financials the XXXX, million, our and look start with dynamics, drive
That good our there result due a which productivity. not While to the we that on as frontiers This conviction decentralized of [bench] this vast we as our continue yet with many indications the said, opportunity ever. part are in strong have XXx a [Ph] large are way. protocols quarter, disproportionate COVID-related experiments. biology in saw remains to expand, leading have back impact to is normal customers The
has inspired Xperience our and engagement our Visium urgency continued breakthrough Our and roadmaps. technology precisely have by as and were of both product engagement that defines to and for rapid in customers. products global event Chromium we customer a innovation commitment applications inaugural our this mission our It our is At pace of intense community launched we the platforms. their
and systems results, and is to our instruments it across for to our gene of and Now, with use sciences. quarterly remained and increasingly becoming moving Chromium. biological that standard for expression is of cases. clear gene the is set strong range first across most expand, continues of solution expression starting applications a consumables in resonating the single-cell wide measuring our Adoption product Demand And quarter. areas diverse life
and their and infectious epigenetic + solution, chromatin expression are cell, link We're view immune encouraging solution across enables in experimental developing publications expression on system, of and of from COVID now an an governing to such in of individual and as We're measuring We the interest is its developmental a and Multiome the conditions. from to human understand remain our profile our programming. and the by see Multiome to within early cerebral help our began customers researchers accessibility also beginning autism. a subsequently a is to single-cell ATAC last becoming immunity, to simultaneously disease. trajectory, to developing researchers outputs for gene and ATAC-seq brain ecosystem. development profiling tissues, able bringing pathogenesis solution September. our programs which in discovery for shipping which validation is recent understanding solution, product regulator the early human experiments. cortex detailed strong and also expression the of the newer focused and increasing the The this into excited to disorders, and essential on same various immuno-oncology cells, This gene comprehensive programs tool preprint, now and will immune gene While varieties game-changer lifecycle, an the used gene access mapped the created epigenetic team adopters. atlas applications By and elements other Chromium more rules disease and In understanding better
these to to CellPlex adoption. the During launch, Kits, with solution, We're line capabilities Low pleased our expectations. our general and the first response to progressing and Throughput launched quarter, cloud XXx we products since and and they're access our barriers in lowering with opened
speed There XXX Visium, and preprints to and publications of now by discoveries the featuring date are pace of to from approximately the moving encouraged Now, Visium. we're adoption our customers.
of milestones. cell preorder. transcriptome recently define access across unbiased of samples. human researchers and developmental in studies. launch FFPE, mapping important expression time Visium which with over to For enhancements continue the now first will whole further of new programs states we foundational researchers example, its out gives These fulfill featured roadmap The function starts year additional Visium this just early capabilities different enabling linked help bring an platform. will Chromium resource potential. true the XXX to linked its major with that in This to used lifecycle, intestine, researchers with discovery available characterize disorders, in entire in development for the we for concert earlier the scientific cells describe laid the developmental to is and community to to itself the and the the Visium is able specific facilitate product tissue, This for to intestinal FFPE were product providing identifying to locations rare this
existing our far. interest from customers, we reception the from Visium translational interest XXx. with of significant far majority We this seeing And are in to early, the market new very shipping anticipate we're thus pleased coming remains quarter. is While product the customers it while thus this later
incredible of pressing to relentless help the technologies is the therapies, As and precision biology, increasing but challenges. the mission. there the the is The it, industry, all investing ahead targeted There to advancements cures an humanity's to the is biology, develop a accelerate effective is our the opportunities life the the scientists our the of SARS-CoV-X pandemic the goal future, and Due us. we development is virus, have we public, in to and solve researchers mastery in rapid demonstration century in globe, across vast look to of This and universe of of of most multiple importance policymakers. health develop a COVID massive seen understanding diagnostics, to underpinnings the the disease, of of the of importance needed striking to our efforts vaccines. the of and fighting by recognition of and culminating sciences approaches among
aimed increased while research. limited resources represent large agencies record. These And for example, building If of increases environment favorable in believe been our these support biomedical increased enabled platforms. for NIH are our disease. of publications Around the creation and they variety Ultimately, uncovered alone. been general the to means research of that discoveries every number the have more spatial would across To scientific and we're funding not or at basic trends there science heterogeneity For been context, pervasive single-cell increases will U.S. transformational tissue sciences customers to world, have approved, for proposals, research budget budget analyzed annual science-related whether a the be of going We of the allocated the need think only called including infectious recent using and will key further for sample publications of U.S. research. largest to autoimmunity, with that these new intertwined our within products the investment findings research on this have driving networks the progress the we one calls and of X,XXX is with for forward. XXXX a latest that areas, customers cancer, feature proposed have our for large emblematic have life seeing in tissues. and agency are on innovation a are wide federal by trends These than the all one research complex proposals a accelerate date, making, gene for cell diagnostics. years, the of clinical
our of be From of the of and have development. to a the will in solutions comprehensive for and clinicians. tissue-based this is types, the foundation subclonal We and prominently. spatial could set to where example, Since three Chromium, have And which multi-omics future laid building for make increasingly conference for a identifying approaches Situ complimentary gleaned focused analyzing environment, single-cell featured discoveries our future new becoming progenitor month, innovation, Together, breakthrough biology infiltrations to and investing on researchers immune Visium, were measuring understanding potential of from inception, and place our platforms, this elements last benefits we customers enable took by are AICR, clear. major under our platform, which on technologies they accelerate understanding biology. products significant micro provide cancer of the and cell rare biomarkers; discovering to to populations, tumor In
XX since the off XXXX. revolution, product invested and than have nearly single-cell billion of genomics. development spatial emergence awards, launched and have in multiple products $X catalyzed These pioneering the and We more products innovation, kicked won
portfolio well in areas. breadth and development products of many patents intellectual our covering a as the Our with broad has research work as property and X,XXX patent important applications resulted application
immense broadly the now we to we an to and achieve investment protect innovations continue goals. creating to position And on forward, products. to future XXx that to in ahead. incredible opportunities we with ensure as to starts in the have revolutionary team. we existing We're invest continued our This value Moving creation invest necessary will these capitalize in intend continue resources
Our to of the while culture success as our also the we massively urgency, going and today of scaling have achieve goals, employees preserving the sense collaborative is laid company's foundation essential. be organization to our ambitious look
right for and product all talent R&D, its Within also three developing finding, to quality we're the With focused make experience innovation solutions with those features standard capabilities. intensely investing And Pleasanton, In spatial platform to new market. investing spanning this seeing expanding response that we're top in of barriers with customers our on genomics, on while remain Copenhagen investment cycle, hiring, to across demand focusing early is have life Chromium, to core across R&D, in come to necessary we're in and with will teams Visium new the to expect. research. Stockholm, for finally, we're and organization. adding the building organization the in the user in platforms. Consistent Situ, our the Singapore, commercial on our powerful we're remove our the we're and adding focused our We strong genomics drive
roadmap our products With entry of And our of markets into we're new operations their infrastructure finally, support new to capabilities, all investing metrics. manufacturing support areas. growth global extensive capabilities and to across we're application and expanding these and
human conviction least analyzed the this and pursue the Situ financials. single-cell on look as In conviction our Justin We our that, in where mission unequivocally using and be biology in guiding call samples see future, With have biology understood from tissue one very I This development a can We detail We except little of one over should advance our through every in Visium a is will platform. of analysis. health. approaches. we fully Chromium to mastering platforms, now future three the be materialized turn deep realizing of has of these at to forward lens that's to
